

## Recent progress of antibody-drug conjugate in breast cancer treatment

Shanu Modi, M.D.

Member, Breast Medicine Service,  
Memorial Sloan Kettering Cancer Center

Associate Professor,  
Weill Cornell Medical College  
New York, NY, U.S.A.

Antibody–drug conjugates (ADCs) are a unique class of anticancer agents, which combine the specificity of monoclonal antibodies toward cellular-antigens with the targeted release of potent cytotoxic drugs, allowing for the potential of increased anticancer efficacy and reduced toxicity compared with traditional chemotherapies.

Advances in synthetic biochemistry methods in monoclonal antibody production, linker technology and novel payload discovery have ushered in a new generation of ADCs with potentially improved tissue specificity and cytotoxicity relative to the previous agents. Many of these new drugs exhibit impressive activity against treatment-refractory cancers.

The aim of this presentation is to review the following topics: 1. Concept of antibody-drug conjugate - the magic bullet. 2. Current clinical trial evidence to extend application of ADCs from HER2+ to HER2- BC. 3. Future perspectives and unanswered questions.